Research
Mixed
Imaging-based body composition assessment (DXA, CT, or MRI) is required to demonstrate that weight loss from anti-obesity drugs is attributable to fat mass reduction rather than lean mass loss, as mandated by updated US FDA and Korean MFDS guidelines.
If you are taking anti-obesity medication, ask your provider about body composition analysis (DXA or CT) rather than relying solely on weight. This ensures your weight loss is coming from fat stores and not muscle tissue, which is critical for long-term metabolic health and is now a regulatory standard for drug approval.
StrongSupportsVERY_HIGH confidence
As the regulatory approval of anti-obesity drugs requires evidence that weight loss is primarily attributable to fat mass reduction, agencies such as the United States Food and Drug Administration (U.S. FDA) and Korean Ministry of Food and Drug Safety (MFDS) recommend including imaging data in clinical trials.
Why this rating
Based on explicit regulatory guidance (FDA 2025, MFDS 2015) and data from pivotal Phase III trials (STEP, SURMOUNT).
Source
Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs
So Yeon Kim et al. · Korean Journal of Radiology · 2026
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →